Health Care [ 6/12 ] | Biotechnology [ 27/74 ]
NASDAQ | Common Stock
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States.
The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials.
It is also developing next generation T-cell engager programs.
The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 5, 25 | -0.82 Decreased by -9.07% | -0.59 Decreased by -38.64% |
| Nov 5, 24 | 0.90 Increased by +221.43% | 0.21 Increased by +328.57% |
| Aug 6, 24 | -0.89 Decreased by -28.99% | -0.59 Decreased by -50.85% |
| May 9, 24 | -0.84 Decreased by -37.70% | -0.64 Decreased by -31.25% |
| Mar 7, 24 | -0.75 Decreased by -457.14% | -0.15 Decreased by -400.00% |
| Nov 6, 23 | 0.28 Increased by +170.00% | -0.10 Increased by +380.00% |
| Aug 9, 23 | -0.69 Decreased by -2.99% | -0.52 Decreased by -32.69% |
| May 9, 23 | -0.61 Increased by +43.52% | 0.45 Decreased by -235.56% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 17.73 M Increased by +65.39% | -15.42 M Increased by +66.53% | Decreased by -86.98% Increased by +79.76% |
| Sep 30, 24 | 110.71 M Increased by +964.81% | 56.31 M Increased by +220.78% | Increased by +50.86% Decreased by -69.87% |
| Jun 30, 24 | 10.80 M Decreased by -17.81% | -55.66 M Decreased by -196.86% | Decreased by -515.55% Decreased by -217.84% |
| Mar 31, 24 | 9.10 M Decreased by -62.40% | -52.19 M Decreased by -36.45% | Decreased by -573.26% Decreased by -262.91% |
| Dec 31, 23 | 10.72 M Decreased by -84.94% | -46.07 M Decreased by -459.88% | Decreased by -429.78% Decreased by -2.49 K% |
| Sep 30, 23 | 10.40 M Decreased by -75.09% | 17.55 M Increased by +171.15% | Increased by +168.84% Increased by +385.61% |
| Jun 30, 23 | 13.14 M Decreased by -49.49% | 57.47 M Increased by +239.14% | Increased by +437.49% Increased by +375.47% |
| Mar 31, 23 | 24.21 M Increased by +126.86% | -38.25 M Increased by +42.27% | Decreased by -157.96% Increased by +74.55% |